郝卫东，博士，工商管理硕士

　　20多年的新药研发经验（大分子，小分子）。现任新加坡科技研究局实验药物开发中心的首席科学家。在此之前，他曾Pfizer, MedImmune, AstraZeneca, Hansoh Bio及 Zencore Biologics任职。

　　他AZD342项目的主要贡献者，该项目正在美国进行临床二期的研究（NCT05737940），中国（JXSL2300044）。

　　他毕业于清华大学，获得纽约州立大学（石溪）分子博士学位及加州大学（圣地亚哥）的工商管理硕士。

　　Weidong Hao，Ph.D., MBA

　　More than 20 years of experience in drug discovery and development. He is the Chief Scientific Officer (CSO) of the Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), Singapore. Prior to joining EDDC, Weidong held various positions of increased responsibility with different companies from Pfizer, MedImmune, AstraZeneca, Hansoh Bio to Zencore Biologics during the last 2 decades.

　　He was the key contributor to AZD3427 (from project initiation to candidate drug and IND filing), which is currently in Phase IIb clinical trial in the US (NCT05737940) and in China (JXSL2300044).

　　A graduate of Tsinghua University in China, Weidong Hao obtained his Ph.D. from SUNY at Stony Brook, and MBA from UCSD.■